Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study Meeting Abstract
| Authors: | Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; Choueiri, T.; Gerritsen, W.; Gurney, H.; Quinn, D.; Culine, S.; Sternberg, C.; Mai, Y.; Puhlmann, M.; Perini, R.; Bajorin, D. |
| Abstract Title: | Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study |
| Meeting Title: | ECCO2017: European Cancer Congress |
| Journal Title: | European Journal of Cancer |
| Volume: | 72 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Jan 27-30 |
| Meeting Location: | Amsterdam, Netherlands |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-02-01 |
| Start Page: | S2 |
| Language: | English |
| ACCESSION: | WOS:000417650200004 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(17)30092-8 |
| Notes: | Meeting Abstract: 3LBA -- ECCO European Cancer Congress -- JAN 27-30, 2017 -- Amsterdam, NETHERLANDS -- Source: Wos |
